Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Applied Microbiology and Biotechnology|August 7, 2010
Methods in mammalian cell line engineering: from random mutagenesis to sequence-specific approachesOliver Krämer, Sandra Klausing, Thomas NollProteins|May 27, 2004
Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulationsChristoph A Sotriffer, Oliver Krämer, Gerhard KlebeJournal of Clinical Microbiology|October 2, 2009
Actinomyces neuii subsp. neuii Associated with periprosthetic infection in total hip arthroplasty as causative agentHeime Rieber, Roman Schwarz, Oliver Krämer, et al.Bioorganic & Medicinal Chemistry Letters|September 10, 2002
Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amidesJochen Wiesner, Andreas Mitsch, Pia Wissner, et al.Journal of Computer-Aided Molecular Design|December 19, 2012
Free enthalpies of replacing water molecules in protein binding pocketsSereina Riniker, Luzi J Barandun, François Diederich, et al.Journal of Clinical Microbiology|May 31, 2002
High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assayLutz Von Müller, Walter Hampl, Joachim Hinz, et al.Journal of Medicinal Chemistry|October 27, 2022
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS<sup>G12C</sup> InhibitorJoachim Bröker, Alex G Waterson, Chris Smethurst, et al.RSC Medicinal Chemistry|December 2, 2024
Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the openClaudia Tredup, Suzanne Ackloo, Hartmut Beck, et al.RSC Medicinal Chemistry|June 26, 2023
Target 2035 - an update on private sector contributionsSuzanne Ackloo, Albert A Antolin, Jose Manuel Bartolome, et al.Pageof 1